Better Buy: Eli Lilly vs. GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) and Eli Lilly (NYSE: LLY) are two of the bigger names in healthcare, and they're great options for investors looking to add safe stocks to their portfolios. They have strong fundamentals, and as these two drug manufacturers continue to produce new and exciting medicines, they'll also provide investors with long-term growth.
Let's look at how they've been doing of late to see which stock has the edge today.
One of the big challenges for Eli Lilly in recent years has been its struggle to generate much growth. Sales of $24.6 billion in 2018 were up a modest 7.4% from 2017's tally of $22.9 billion. And they've only grown 25% since 2014, when Eli Lilly reported revenue of $19.6 billion. The positive is that the company's bottom line has remained in the black in four of the past five years, with the only blemish relating to a large income tax bill in 2017.
Source Fool.com
